Highlights

  • Ryoncil generated US$36 million in net revenue for the fourth quarter of FY26
  • Full-year net revenue reached US$115 million in Ryoncil's first full year of sales
  • CEO Dr Silviu Itescu says uptake has exceeded initial revenue projections
  • New five-year financing facility frees up capital for label-extension and pipeline initiatives

Mesoblast Limited (ASX:MSB; Nasdaq:MESO) has reported net revenue of US$36 million for its lead product Ryoncil (remestemcel-L-rknd) for the fourth quarter ended 30 June 2026, taking full-year net revenue to US$115 million in the product's first full year on the market.

The global leader in allogeneic cellular medicines for inflammatory diseases said the result reflects strong and continuing uptake of Ryoncil since its launch, with revenue already ahead of the company's initial internal projections. Chief Executive Dr Silviu Itescu said the company anticipates further revenue growth in the coming fiscal year, driven by ongoing momentum across major U.S. paediatric treatment centres.

Dr Itescu also pointed to the strength of Mesoblast's balance sheet, noting that operational activities are now largely funded through revenue growth. A newly secured five-year financing facility has freed up capacity that would otherwise have been tied to funding day-to-day operations, allowing management to direct resources toward label-extension studies and other strategic initiatives across the company's pipeline.

Ryoncil holds a significant place in the cell therapy landscape as the first mesenchymal stromal cell (MSC) product approved by the U.S. Food and Drug Administration for any indication. It remains the only FDA-approved therapy specifically for children aged two months and older with steroid-refractory acute graft-versus-host disease (SR-aGvHD), a serious and often life-threatening complication that can occur after a bone marrow or stem cell transplant.

Beyond its approved paediatric indication, Mesoblast is working to expand Ryoncil's reach into SR-aGvHD in adults and into biologic-resistant inflammatory bowel disease. The company's second cell therapy platform, built around rexlemestrocel-L, is in development for heart failure and chronic low back pain. Mesoblast has also established commercial partnerships in Japan, Europe and China to support the broader rollout of its allogeneic cell therapy platforms.

The company's manufacturing operations, which produce industrial-scale, cryopreserved, off-the-shelf cellular medicines, span facilities in Australia, the United States and Singapore. Mesoblast holds an extensive intellectual property position, with more than 1,000 granted patents or patent applications covering its cell therapy compositions, manufacturing methods and clinical indications, providing protection in major markets through to at least 2044.

Conclusion

Mesoblast's first full year of Ryoncil commercialisation has delivered revenue ahead of expectations, giving the company a stronger financial footing from which to pursue label extensions and advance its broader cell therapy pipeline. With paediatric SR-aGvHD sales now established and additional indications in development, the coming fiscal year will be a key test of whether the current growth trajectory can be sustained.